Peroxisome proliferator-activated receptor γ as a novel target in cancer therapy: Binding and activation by an aromatic fatty acid with clinical antitumor activity

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 933-941

  Samid, Dvorit ^a   Wells, Michelle ^a   Greene, Marianne E ^b   Shen, Weiyin ^a   Palmer, Colin N A ^c   Thibault, Alain ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; FATTY ACID; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENYLACETIC ACID; PHENYLACETIC ACID DERIVATIVE; PROTEIN P21;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL DIVISION; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; PHENYLACETATES; PHOSPHORYLATION; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0034071190     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Samid, D., Shack, S., and Sherman, L. T. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res., 52: 1988-1992, 1992.
2. Samid, D., Hudgins, W. R., Shack, S., Liu, L., Prasanna, P., and Myers, C. E. Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv. Exp. Med. Biol., 400A: 501-505, 1997.
3. Hudgins, W. R., Shack, S., Myers, C. E., and Samid, D. Cytostatic activity of phenylacetate and derivatives against tumor cells. Correlation with lipophilicity and inhibition of protein prenylation. Biochem. Pharmacol., 50: 1273-1279, 1995.
4. Liu, L., Shack, S., Stetler-Stevenson, W. G., Hudgins, W. R., and Samid, D. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J. Investig. Dermatol., 103: 335-340, 1994.
5. Call, T. G., Stenson, M. J., and Witzig, T. E. Effects of phenylacetate on cells from patients with B-chronic lymphocytic leukemia. Leuk. Lymphoma, 14: 145-149, 1994.
6. Carducci, M. A., Nelson, J. B., Chan-Tack, K. M., Ayyagari, S. R., Sweatt, W. S., Campbell, P. A., Nelson, W. G., and Simons, J. W. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res., 2: 379-387, 1996.
7. Shack, S., Miller, A., Liu, L., Prasanna, P., Thibault, A., and Samid, D. Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate. Clin. Cancer Res., 2: 865-872, 1996.
8. Gore, S. D., Samid, D., and Weng, L. J. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation and apoptosis of primary neoplastic myeloid cells. Clin. Cancer Res., 3: 1755-1762, 1997.
9. Thibault, A., Cooper, M. R., Figg, W. D., Venzon, D. J., Sartor, A. O., Tompkins, A. C., Weinberger, M. S., Headlee, D. J., McCall, N. A., Samid, D., and Myers, C. E. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res., 54: 1690-1694, 1994.
10. Thibault, A., Samid, D., Cooper, M. R., Figg, W. D., Tompkins, A. C., Patronas, N., Headlee, D. J., Kohler, D. R., Venzon, D. J., and Myers, C. E. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer (Phila.), 75: 2932-2938, 1995.
11. Prados, M. D., Spence, A., Schold, C., Robbins, I., Mehta, M. M., Berger, M., Kuhn, J., Rector, J., Chang, S., and Gilbert, M. A Phase II trial of phenylacetic acid for recurrent glioma. Preliminary report of the North American Brain Tumor Consortium. Proc. Am. Soc. Clin. Oncol., 15: A288, 1996.
12. Thibault, A., Figg, W. D., and Samid, D. A Phase I study of the differentiating agent phenylbutyrate in patents with cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 15: A1539, 1996.
13. Carducci, M., Bowling, M. K., Eisenberger, M., Sinibaldi, V., Chen, T., Noe, D., Grochow, L., and Donehower, R. Phenylbutyrate (PB) for refractory solid tumors: Phase I clinical and pharmacological evaluation of intravenous and oral PB. Anticancer Res., 17: 3972-3973, 1997.
14. Gore, S. D., Miller, C. B., Weng, L-J., Burks, K., Griffin, C. A., Chen, T. L., Smith, V., Burke, P. J., Grever, M., and Rowinsky, E. K. Clinical development of sodium phenylbutyrate (SPB) as a putative differentiating agent in myeloid malignancies. Anticancer Res., 17: 3981-3982, 1997.
15. Warrell, R. P., He, L-Z., Richon, V., Calleja, E., and Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst., 90: 1621-1625, 1998.
16. Samid, D., Ram, Z., Hudgins, W. R., Shack, S., Liu, L., Walbridge, S., Oldfield, E. H., and Myers, C. E. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res., 54: 891-895, 1994.
17. Lea, M. A., and Randolph, V. M. Induction of reporter gene expression by inhibitors of histone deacetylase. Anticancer Res., 18: 2717-2721, 1998.
18. Prasanna, P., Shack, S. W. V. L., and Samid, D. Phenylacetate in chemoprevention: in vitro and in vivo suppression of 5-aza-2′-deoxycytidine-induced carcinogenesis. Clin. Cancer Res., 1: 865-871, 1995.
19. Pineau, T., Hudgins, W. R., Liu, L., Chen, L. C., Sher, T., Gonzalez, F. J., and Samid, D. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem. Pharmacol., 52: 659-667, 1996.
20. Tugwood, J. D., Aldridge, T. C., Lambe, K. G., Macdonald, N., and Woodyatt, N. J. Peroxisome proliferator-activated receptors: structures and function. Ann. NY Acad. Sci., 804: 252-265, 1996.
21. Greene, M. E., Blumberg, B., McBride, O. W., Yi, H. F., Kronquist, K., Kwan, K., Hsieh, L., Greene, G., and Nimer, S. D. Isolation of the human peroxisome proliferator activated receptor γ cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr., 4: 281-299, 1995.
22. Spiegelman, B. M. PPAR-γ-adipogenic regulator and thiazolidinedione receptor. Diabetes, 47: 507-514, 1998.
23. Gorospe, M., Shack, S., Guyton, K. Z., Samid, D., and Holbrook, N. J. Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate. Cell Growth Differ., 7: 1609-1615, 1996.
24. Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., and Lehmann, J. M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. USA, 94: 4318-4323, 1997.
25. Palmer, C. N. A., and Wolf, C. R. cis-Parinaric acid is a ligand for the human peroxisome proliferator activated receptor γ-development of a novel spectrophotometric assay for the discovery of PPAR-γ ligands. FEBS Lett., 431: 476-480, 1998.
26. Camp, H. S., and Tafuri, S. R. Regulation of peroxisome proliferator-activated receptor γ activity by mitogen-activated protein kinase. J. Biol. Chem., 272: 10811-10816, 1997.
27. Issemann, I., and Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators [see comments]. Nature (Lond.), 347: 645-650, 1990.
28. Vidal-Puig, A. J., Considine, R. V., Jimenez-Linan, M., Werman, A., Pories, W. J., Caro, J. F., and Flier, J. S. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Investig., 99: 2416-2422, 1997.
29. Jiang, C. Y., Ting, A. T., and Seed, B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature (Lond.), 391: 82-86, 1998.
30. Forman, B. M., Chen, J., and Evans, R. M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl. Acad. Sci. USA, 94: 4312-4317, 1997.
31. Samid, D., Kulkarni, M., Liu, L., and Thibault, A. The nuclear receptors, PPARα and PPAR-γ, are molecular targets of the differentiation inducers phenylacetate and phenylbutyrate. Proc. Annu. Meet. Am. Assoc. Cancer Res., 38: A3024, 1997.
32. Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., Evans, R. M., and Spiegelman, B. M. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc. Natl. Acad. Sci. USA, 94: 237-241, 1997.
33. Sarraf, P., Mueller, E., Jones, D., King, F. J., Deangelo, D. J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., and Spiegelman, B. M. Differentiation and reversal of malignant changes in colon cancer through PPAR-γ. Nat. Med., 4: 1046-1052, 1998.
34. Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., and Spiegelman, B. M. Terminal differentiation of human breast cancer through PPAR-γ. Mol. Cell, 1: 465-470, 1998.
35. Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., Said, J. W., Holden, S., Miyoshi, I., and Koeffler, H. P. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res., 58: 3344-3352, 1998.
36. Heinzel, T., Lavinsky, R. M., Mullen, T. M., Soderstrom, M., Laherty, C. D., Torchia, J., Yang, W. M., Brard, G., Ngo, S. D., Davie, J. R., Seto, E., Eisenman, R. N., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression [see comments]. Nature (Lond.), 387: 43-48, 1997.
37. Gilman, A. G., Rall, T. W., Nies, A. S., and Taylor, P. Goodman and Gilman's the Pharmacological Basis of Therapeutics, Ed. 8. Oxford: Pergamon Press, 1990.
38. Serabe, B., Adamson, P., Wolfe, R., Balis, F., Packer, R., Aleksic, A., Jakacki, R., and Blaney, S. Phase I trial and pharmacokinetic (PK) study of phenylacetate (PA) given as a 28-day continuous infusion (CIVI) in children. Proc. Am. Assoc. Cancer Res., 38: A661, 1997.
39. Green, S. Peroxisome proliferators: a model for receptor mediated carcinogenesis. Cancer Surv., 14: 221-232, 1992.
40. Lefebvre, A. M., Chen, I. H., Desreumaux, P., Najib, J., Fruchart, J. C., Geboes, K., Briggs, M., Heyman, R., and Auwerx, J. Activation of the peroxisome proliferator-activated receptor y promotes the development of colon tumors in C57bl/6j-Apc(Min)/+ mice. Nat. Med., 4: 1053-1057, 1998.
41. Saez, E., Tontonoz, P., Nelson, M. C., Alvarez, J. G. A., Ming, U. T., Baird, S. M., Thomazy, V. A., and Evans, R. M. Activators of the nuclear receptor PPAR-γ enhance colon polyp formation. Nat. Med., 4: 1058-1061, 1998.
42. Seed, B. PPAR-γ and colorectal carcinoma-conflicts in a nuclear family. Nat. Med., 4: 1004-1005, 1998.
43. Cattley, R. C., Deluca, J., Elcombe, C., Fennercrisp, P., Lake, B. G., Marsman, D. S., Pastoor, T. A., Popp, J. A., Robinson, D. E., Schwetz, B., Tugwood, J., and Wahli, W. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans. Regul. Toxicol. Pharmacol., 27: 47-60, 1998.
44. Palmer, C. N., Hsu, M. H., Griffin, K. J., Raucy, J. L., and Johnson, E. F. Peroxisome proliferator activated receptor-α expression in human liver. Mol. Pharmacol., 53: 14-22, 1998.
45. Oliver, M. F., Heady, J. A., Morris, J. N., and Cooper, M. J. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br. Heart J., 40: 1069-1118, 1978.
46. DuBois, R. N., Gupta, R., Brockman, J., Reddy, B. S., Krakow, S. L., and Lazar, M. A. The nuclear eicosanoid receptor PPARγ is aberrantly expressed in colonic cancers. Carcinogenesis (Lond.), 19: 49-53, 1998.
47. Simell, O., Sipila, I., Rajantie, J., Valle, D. L., and Brusilow, S. W. Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. Pediatr. Res., 20: 1117-1121, 1986.
48. Dover, G. J., Brusilow, S., and Charache, S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood, 84: 339-343, 1994.
49. Olivieri, N. F., Rees, D. C., Ginder, G. D., Thein, S. L., Brittenham, G. M., Waye, J. S., and Weatherall, D. J. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet, 350: 491-492, 1997.
50. Prasanna, P., Thibault, A., Liu, L., and Samid, D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J. Neurochem., 66: 710-716, 1996.
51. Bookman, M. A. Biological therapy of ovarian cancer: current directions. Semin. Oncol., 25: 381-396, 1998.